GGHC
DNA icon

Gilder Gagnon Howe & Co’s Ginkgo Bioworks DNA Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,266
Closed -$1.49M – 260
2022
Q1 		$1.49M Sell
9,266
-9,664
-51% -$1.88M 0.01% 235
2021
Q4 		$6.29M Buy
+18,930
New +$8.99M 0.04% 202

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Gilder Gagnon Howe & Co's DNA Position: Q2 2022 in Review

Gilder Gagnon Howe & Co sold out of Ginkgo Bioworks (DNA) in Q2 2022, closing a stake of 9,266 shares — an estimated $1.49M sold.

Gilder Gagnon Howe & Co first reported a position in DNA in Q4 2021 and held it in 2 quarters. The position peaked at $6.29M in Q4 2021. 260 funds tracked by Wall St. Rank hold DNA as of Q2 2022.

  • Gilder Gagnon Howe & Co reported no remaining Ginkgo Bioworks position as of Q2 2022 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 9,266 Ginkgo Bioworks shares in Q2 2022, an estimated $1.49M.
  • Gilder Gagnon Howe & Co first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 2 quarters.
  • Gilder Gagnon Howe & Co's Ginkgo Bioworks position peaked at $6.29M in Q4 2021.
  • 260 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2022.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2022, filed 15 Aug 2022.